• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

我们如何治疗癌症疾病而非癌细胞?

How Can We Treat Cancer Disease Not Cancer Cells?

作者信息

Kim Kyu-Won, Lee Su-Jae, Kim Woo-Young, Seo Ji Hae, Lee Ho-Young

机构信息

SNU-Harvard NeuroVascular Protection Research Center, College of Pharmacy, Seoul National University, Seoul, Korea.

Laboratory of Molecular Biochemisty, Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul, Korea.

出版信息

Cancer Res Treat. 2017 Jan;49(1):1-9. doi: 10.4143/crt.2016.606. Epub 2016 Dec 26.

DOI:10.4143/crt.2016.606
PMID:28052653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5266380/
Abstract

Since molecular biology studies began, researches in biological science have centered on proteins and genes at molecular level of a single cell. Cancer research has also focused on various functions of proteins and genes that distinguish cancer cells from normal cells. Accordingly, most contemporary anticancer drugs have been developed to target abnormal characteristics of cancer cells. Despite the great advances in the development of anticancer drugs, vast majority of patients with advanced cancer have shown grim prognosis and high rate of relapse. To resolve this problem, we must reevaluate our focuses in current cancer research. Cancer should be considered as a systemic disease because cancer cells undergo a complex interaction with various surrounding cells in cancer tissue and spread to whole body through metastasis under the control of the systemic modulation. Human body relies on the cooperative interaction between various tissues and organs, and each organ performs its specialized function through tissue-specific cell networks. Therefore, investigation of the tumor-specific cell networks can provide novel strategy to overcome the limitation of current cancer research. This review presents the limitations of the current cancer research, emphasizing the necessity of studying tissue-specific cell network which could be a new perspective on treating cancer disease, not cancer cells.

摘要

自分子生物学研究开始以来,生物科学研究一直聚焦于单细胞分子水平上的蛋白质和基因。癌症研究也集中在区分癌细胞与正常细胞的蛋白质和基因的各种功能上。因此,大多数当代抗癌药物都是针对癌细胞的异常特征开发的。尽管抗癌药物的开发取得了巨大进展,但绝大多数晚期癌症患者的预后仍然严峻,复发率很高。为了解决这个问题,我们必须重新评估当前癌症研究的重点。癌症应被视为一种全身性疾病,因为癌细胞在癌症组织中与周围各种细胞发生复杂的相互作用,并在全身调节的控制下通过转移扩散到全身。人体依赖于各种组织和器官之间的协同相互作用,每个器官通过组织特异性细胞网络执行其特定功能。因此,研究肿瘤特异性细胞网络可以为克服当前癌症研究的局限性提供新策略。本综述阐述了当前癌症研究的局限性,强调了研究组织特异性细胞网络的必要性,这可能为治疗癌症疾病而非癌细胞提供一个新的视角。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/28867e0ad606/crt-2016-606f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/efca7119198f/crt-2016-606f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/ea45e5bd36a5/crt-2016-606f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/747040ccb40c/crt-2016-606f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/9f907baf1c9a/crt-2016-606f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/c8051ab0fff6/crt-2016-606f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/9b31c0d57f61/crt-2016-606f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/f172eb5019d9/crt-2016-606f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/28867e0ad606/crt-2016-606f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/efca7119198f/crt-2016-606f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/ea45e5bd36a5/crt-2016-606f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/747040ccb40c/crt-2016-606f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/9f907baf1c9a/crt-2016-606f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/c8051ab0fff6/crt-2016-606f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/9b31c0d57f61/crt-2016-606f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/f172eb5019d9/crt-2016-606f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7f6/5266380/28867e0ad606/crt-2016-606f8.jpg

相似文献

1
How Can We Treat Cancer Disease Not Cancer Cells?我们如何治疗癌症疾病而非癌细胞?
Cancer Res Treat. 2017 Jan;49(1):1-9. doi: 10.4143/crt.2016.606. Epub 2016 Dec 26.
2
Targeting Biophysical Cues: a Niche Approach to Study, Diagnose, and Treat Cancer.靶向生物物理线索:一种研究、诊断和治疗癌症的独特方法。
Trends Cancer. 2018 Apr;4(4):268-271. doi: 10.1016/j.trecan.2018.02.006. Epub 2018 Mar 12.
3
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.癌症的先进靶向疗法:药物纳米载体,化疗的未来。
Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23.
4
Autophagy: shaping the tumor microenvironment and therapeutic response.自噬:塑造肿瘤微环境和治疗反应。
Trends Mol Med. 2013 Jul;19(7):428-46. doi: 10.1016/j.molmed.2013.04.005. Epub 2013 May 25.
5
Advances in mechanism and treatment strategy of cancer.癌症的机制与治疗策略进展
Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):1-3.
6
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.微环境酸度作为肿瘤化疗耐药性的主要决定因素:质子泵抑制剂(PPIs)作为一种新的治疗方法。
Drug Resist Updat. 2015 Nov;23:69-78. doi: 10.1016/j.drup.2015.08.004. Epub 2015 Aug 22.
7
[Cancer chemotherapy; past, present and future--from the aspect of fundamental studies].[癌症化疗;过去、现在与未来——从基础研究的角度]
Gan To Kagaku Ryoho. 2003 Oct;30(10):1398-403.
8
Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention.肺癌中的肿瘤-基质相互作用:治疗干预的新候选靶点。
Expert Opin Investig Drugs. 2012 Aug;21(8):1107-22. doi: 10.1517/13543784.2012.693478. Epub 2012 Jun 6.
9
Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.纳米医学用于靶向癌症治疗:克服耐药性。
Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16.
10
Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.信号转导子和转录激活子 3 作为癌症和肿瘤微环境的治疗靶点。
Arch Pharm Res. 2016 Aug;39(8):1085-99. doi: 10.1007/s12272-016-0795-8. Epub 2016 Aug 11.

引用本文的文献

1
Quercetin as a Potential Therapeutic Agent for Malignant Melanoma-A Review of Current Evidence and Future Directions.槲皮素作为恶性黑色素瘤的潜在治疗药物——当前证据与未来方向综述
Medicina (Kaunas). 2025 Apr 2;61(4):656. doi: 10.3390/medicina61040656.
2
New Breakthroughs in the Diagnosis of Leptomeningeal Carcinomatosis: A Review of Liquid Biopsies of Cerebrospinal Fluid.软脑膜癌病诊断的新突破:脑脊液液体活检综述
Cureus. 2024 Feb 28;16(2):e55187. doi: 10.7759/cureus.55187. eCollection 2024 Feb.
3
Equine Melanocytic Tumors: A Narrative Review.

本文引用的文献

1
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.子宫内膜癌进展及腹盆腔转移的基因组格局与演变
Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.
2
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.克服 CDK4/6 抑制剂治疗 HER2 阳性乳腺癌的耐药性
Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006.
3
The Cellular Phase of Alzheimer's Disease.阿尔茨海默病的细胞期。
马黑素细胞瘤:一篇叙述性综述。
Animals (Basel). 2023 Jan 10;13(2):247. doi: 10.3390/ani13020247.
4
The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients.循环中CD81阳性小细胞外囊泡的脂肪酸和蛋白质谱与黑色素瘤患者的疾病分期相关。
Cancers (Basel). 2021 Aug 18;13(16):4157. doi: 10.3390/cancers13164157.
5
Mechanisms of resistance to chemotherapy in non-small cell lung cancer.非小细胞肺癌化疗耐药的机制。
Arch Pharm Res. 2021 Feb;44(2):146-164. doi: 10.1007/s12272-021-01312-y. Epub 2021 Feb 19.
Cell. 2016 Feb 11;164(4):603-15. doi: 10.1016/j.cell.2015.12.056.
4
Hypoxia-Sensitive Metal β-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis.对缺氧敏感的金属β-酮亚胺配合物通过诱导单链DNA断裂和凋亡导致癌细胞死亡。
J Med Chem. 2015 Jun 25;58(12):4940-53. doi: 10.1021/acs.jmedchem.5b00455. Epub 2015 Jun 8.
5
The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.癌症基因组图谱(TCGA):一个不可估量的知识来源。
Contemp Oncol (Pozn). 2015;19(1A):A68-77. doi: 10.5114/wo.2014.47136.
6
The history of monoclonal antibody development - Progress, remaining challenges and future innovations.单克隆抗体的发展历程——进展、尚存挑战及未来创新
Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6. doi: 10.1016/j.amsu.2014.09.001. eCollection 2014 Dec.
7
Chalcones incorporated pyrazole ring inhibit proliferation, cell cycle progression, angiogenesis and induce apoptosis of MCF7 cell line.含有吡唑环的查耳酮可抑制MCF7细胞系的增殖、细胞周期进程、血管生成并诱导其凋亡。
Anticancer Agents Med Chem. 2014;14(9):1282-92. doi: 10.2174/187152061409141010114547.
8
A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.一种具有卓越抗肿瘤活性和新型作用模式的双特异性靶向HER2的飞鼠单克隆抗体。
Mol Cancer Ther. 2014 Aug;13(8):2030-9. doi: 10.1158/1535-7163.MCT-14-0046-T. Epub 2014 Jul 3.
9
Rethinking the war on cancer.重新思考抗癌之战。
Lancet. 2014 Feb 8;383(9916):558-63. doi: 10.1016/S0140-6736(13)62226-6. Epub 2013 Dec 16.
10
Development, maintenance and disruption of the blood-brain barrier.血脑屏障的发育、维持和破坏。
Nat Med. 2013 Dec;19(12):1584-96. doi: 10.1038/nm.3407. Epub 2013 Dec 5.